---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-114839"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-10-16T23:59:59+00:00"
generated_at: "2026-05-30T13:52:21.971695+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio receives FDA clearance to evaluate ADI-001 in IIM and Stiff Person Syndrome

## Summary
- FDA cleared IND amendment for ADI-001 to treat idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS).
- Patient enrollment for IIM/SPS cohort expected to start Q1 2025; Phase 1 now covers six autoimmune diseases.
- Phase 1 program has four arms: LN/SLE, SSc, AAV, and combined IIM/SPS cohort.
- Initial clinical data from Phase 1 in autoimmune diseases expected first half of 2025.

## SEC filing metadata
- accession: 0000950170-24-114839
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-10-16T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024114839/0000950170-24-114839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024114839/acet-20241016.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-114839
- JSON: https://secwatch.observer/filing/0000950170-24-114839.json
- Plain text: https://secwatch.observer/filing/0000950170-24-114839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.